{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:40:33Z","timestamp":1740112833840,"version":"3.37.3"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.intimp.2021.108043","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T07:21:00Z","timestamp":1628061660000},"page":"108043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial"],"prefix":"10.1016","volume":"99","author":[{"given":"Saghar","family":"Barati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed","family":"MohammadReza Hashemian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payam","family":"Tabarsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atefeh","family":"Abedini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahshid","family":"Ashrafzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Haseli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Abtahian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Yousefian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Dastan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Sobhanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzaneh","family":"Dastan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2021.108043_b0005","doi-asserted-by":"crossref","DOI":"10.1097\/CM9.0000000000000744","article-title":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province","volume":"133","author":"Liu","year":"2020","journal-title":"Chin. Med. J."},{"issue":"1","key":"10.1016\/j.intimp.2021.108043_b0010","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2021.108043_b0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3345\/cep.2020.00759","article-title":"Immunopathogenesis of COVID-19 and early immunomodulators","volume":"63","author":"Lee","year":"2020","journal-title":"Clin. Experimental Pediatrics"},{"key":"10.1016\/j.intimp.2021.108043_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106869","article-title":"Promising effects of tocilizumab in COVID-19: a non-controlled, prospective clinical trial","volume":"88","author":"Dastan","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2021.108043_b0025","doi-asserted-by":"crossref","first-page":"e653","DOI":"10.1016\/S2665-9913(20)30309-X","article-title":"Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment","volume":"2","author":"Robinson","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"18","key":"10.1016\/j.intimp.2021.108043_b0030","doi-asserted-by":"crossref","first-page":"9279","DOI":"10.1128\/JVI.00659-06","article-title":"Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein","volume":"80","author":"Chan","year":"2006","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108043_b0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1242\/jeb.090738","article-title":"The mitochondrial unfolded protein response, a conserved stress response pathway with implications in health and disease","volume":"217","author":"Jovaisaite","year":"2014","journal-title":"J. Exp. Biol."},{"issue":"20","key":"10.1016\/j.intimp.2021.108043_b0040","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1016\/j.jmb.2016.08.001","article-title":"A novel in vitro CypD-mediated p53 aggregation assay suggests a model for mitochondrial permeability transition by chaperone systems","volume":"428","author":"Lebedev","year":"2016","journal-title":"J. Mol. Biol."},{"issue":"10","key":"10.1016\/j.intimp.2021.108043_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002331","article-title":"The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors","volume":"7","author":"Pfefferle","year":"2011","journal-title":"PLoS. Pathog."},{"issue":"Pt 8","key":"10.1016\/j.intimp.2021.108043_b0050","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1099\/vir.0.052910-0","article-title":"MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-\u03b1 treatment","volume":"94","author":"de Wilde","year":"2013","journal-title":"J. General Virol."},{"key":"10.1016\/j.intimp.2021.108043_b0055","article-title":"Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia","author":"Sanchez-Pernaute","year":"2020","journal-title":"Reumatolog\u00eda. Cl\u00ednica."},{"issue":"7","key":"10.1016\/j.intimp.2021.108043_b0060","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/microorganisms8070977","article-title":"Calcineurin inhibitor-based immunosuppression and COVID-19: results from a multidisciplinary cohort of patients in northern Italy","volume":"8","author":"Cavagna","year":"2020","journal-title":"Microorganisms"},{"issue":"5","key":"10.1016\/j.intimp.2021.108043_b0065","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3390\/v5051250","article-title":"Suppression of coronavirus replication by cyclophilin inhibitors","volume":"5","author":"Tanaka","year":"2013","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.intimp.2021.108043_b0070","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/joim.13223","article-title":"Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease: A pilot study","volume":"289","author":"G\u00e1lvez-Romero","year":"2021","journal-title":"J. Intern. Med."},{"issue":"6","key":"10.1016\/j.intimp.2021.108043_b0075","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/joim.13264","article-title":"Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: are concentrations required clinically achievable?","volume":"289","author":"Solanich","year":"2021","journal-title":"J. Intern. Med."},{"issue":"6","key":"10.1016\/j.intimp.2021.108043_b0080","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1681\/ASN.2020030348","article-title":"COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm?","volume":"31","author":"Willicombe","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.intimp.2021.108043_b0085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.bjid.2020.06.005","article-title":"Calcineurin inhibitors revisited: A new paradigm for COVID-19?","volume":"24","author":"Hage","year":"2020","journal-title":"Brazilian J. Infectious Diseases"},{"issue":"7","key":"10.1016\/j.intimp.2021.108043_b0090","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Japan Academy Series B, Phys. Biol. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2021.108043_b0095","first-page":"1192","article-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921006792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921006792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T20:15:39Z","timestamp":1730837739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921006792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":19,"alternative-id":["S1567576921006792"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108043","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108043"}}